KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Assets (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Non-Current Assets data on record, last reported at $20.0 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 6.96% year-over-year to $20.0 million; the TTM value through Sep 2025 reached $109.8 million, down 48.46%, while the annual FY2024 figure was $42.6 million, 36.79% down from the prior year.
  • Non-Current Assets reached $20.0 million in Q3 2025 per NKTR's latest filing, down from $21.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $357.5 million in Q1 2021 and bottomed at $20.0 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $142.0 million, with a median of $73.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: plummeted 76.19% in 2023, then grew 7.78% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $321.6 million in 2021, then crashed by 48.81% to $164.6 million in 2022, then plummeted by 59.1% to $67.3 million in 2023, then tumbled by 36.79% to $42.6 million in 2024, then crashed by 53.03% to $20.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $20.0 million in Q3 2025, $21.0 million in Q2 2025, and $26.3 million in Q1 2025.